Edward Kim - Concepedia

Author

Edward Kim

Also Known As

David Ettinger, Donna Thompson, E. Kim, E.J. Kim, Edward J Kim, Edward J. Kim, Edward Jae-Hoon Kim, Edward Jae-hoon Kim, Edward Kim, Sameh Said

291

Publications

Citations

H-Index

107

Concepts

All Affiliations

University of California, Davis The University of Texas MD Anderson Cancer Center UC Davis Comprehensive Cancer Center University of Michigan Moffitt Cancer Center

About

Edward Kim is an author at University of California, Davis specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	37	2.4K
2	Health Sciences	11	12	923
3	Education	1	1	13
4	Engineering	1	1	18
5	Natural Sciences	1	1	20

Edward Kim

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer Hervé Tiriac, Pascal Belleau, Dannielle D. Engle, Cancer Discovery	2018	1.1K
Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis Jae‐Seok Roe, Chang‐Il Hwang, Tim D.D. Somerville, Cell Tumor BiologyPancreatic CancerMedicineCancer BiologyCell Biology	2017	467
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study Allen M. Chen, Carol Felix, Pin‐Chieh Wang, The Lancet Oncology Cancer-associated VirusRadiation TherapyMedicineNasopharyngeal CancerReduced-dose Radiotherapy	2017	318
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma Edward Kim, Vaibhav Sahai, Ethan V. Abel, Clinical Cancer Research	2014	302
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021 Margaret von Mehren, John M. Kane, Marilyn M. Bui, Journal of the National Comprehensive Cancer Network Surgical OncologyNccn Guidelines InsightsGastroenterologyPathologySurgery	2020	296
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study Philip A. Philip, Jill Lacy, Fabienne Portales, The Lancet. Gastroenterology & hepatology Open-label Phase 2Pancreatic CancerGastrointestinal OncologyMedicinePharmacology	2020	227
Podoplanin: A Novel Marker for Oral Cancer Risk in Patients With Oral Premalignancy Hidetoshi Kawaguchi, Adel K. El‐Naggar, Vali Papadimitrakopoulou, Journal of Clinical Oncology	2008	209
Urinary Chemokines CXCL9 and CXCL10 Are Noninvasive Markers of Renal Allograft Rejection and BK Viral Infection Jennifer A. Jackson, Edward Kim, Beth Begley, American Journal of Transplantation	2011	196
A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer Edward Kim, Edgar Ben‐Josef, Joseph M. Herman, Cancer	2013	179
The Notch Pathway Is Important in Maintaining the Cancer Stem Cell Population in Pancreatic Cancer Ethan V. Abel, Edward Kim, Jingjiang Wu, PLoS ONE	2014	162

Page 1